Healthcare -
Biotechnology - NYSE - US
$ 2.09
-12.2 %
$ 708 M
Market Cap
-0.99
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Nuvation Bio Inc.
| Net Income | -568 M |
| Depreciation & Amortization | 683 K |
| Capital Expenditures | -162 K |
| Stock-Based Compensation | 32.3 M |
| Change in Working Capital | 0 |
| Others | 405 M |
| Free Cash Flow | -131 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (567.9) | (75.8) | (104.2) | (86.8) | (41.7) | (33.6) | (1.0) |
| Depreciation & Amortization | 0 | 0.2 | 0.2 | 0.2 | 0.1 | 13 K | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0.4 | 0 | 0 | 0 |
| Stock Based Compensation | 32.3 | 19.5 | 16.3 | 9.3 | 2.2 | 0 | 0 |
| Other Operating Activities | 405.3 | (12.5) | (5.0) | 4.0 | 0.7 | 9.6 | 0.1 |
| Change in Working Capital | 0 | 0.5 | (3.4) | 4.8 | 2.1 | (0.5) | 0.3 |
| Cash From Operations | (130.4) | (68.0) | (96.1) | (68.2) | (36.5) | (24.4) | (0.6) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (0.2) | 69 K | (0.4) | (0.3) | (0.1) | (0.7) | 0 |
| Other Items | 122.9 | 9.0 | 63.8 | (454.4) | (70.2) | (115.2) | 0 |
| Cash From Investing Activities | 122.7 | 8.9 | 63.5 | (454.7) | (70.3) | (115.9) | 0 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (4.6) | 0 | 0 | 0 | 0 | 15.0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.9 | 0.6 | 1.3 | 625.5 | (2.5) | 128.6 | 0.8 |
| Cash From Financing Activities | 0.3 | 0.6 | 1.3 | 625.5 | 133.1 | 143.6 | 0.8 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (6.9) | (58.5) | (31.3) | 102.7 | 26.3 | 3.3 | 0.2 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (130.6) | (68.1) | (96.5) | (68.5) | (36.7) | (25.1) | (0.6) |